A single centre experience in treating localised prostate cancer with focal HIFU ablation over 8 years
BAUS ePoster online library. Johnston M.
Jun 26, 2018; 211343
Mr. Maximilian Johnston
Mr. Maximilian Johnston
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
Introduction: With improving accuracy in diagnosis and identification of index prostate cancer lesions, focal ablation has become a more palatable approach for treating significant unilateral disease, this technique was adopted in our centre 8 years ago. Here we report our intermediate outcomes.

Patients and Methods: 149 men underwent partial gland HIFU. Diagnostics included PSA, MpMRI, mapping biopsies followed by focal ablation of significant cancer as defined by the UCL criteria. Follow-up MRI, PSA, QOL questionnaires, biopsy for cause, and redo HIFU if required as part of the treatment strategy per EAU International Multidisciplinary Consensus on Trial Design for Focal Therapy guidelines.

Results: Mean age of 66 years, 89% of subjects had intermediate/high risk disease, and mean pre-HIFU PSA was 7.4. 31% had high volume Gleason 6 disease, 55% had Gleason 3+4 disease, and 13% had Gleason 4+3 disease. 61% received a Hemi-ablation, 31% a focal ablation, and 8% a quadrant ablation. Mean follow-up was 40 months, subjects' PSA dropped to an average 70% nadir. 8% had BCR. 6% required salvage treatment (five men underwent radical prostatectomy, four with radiotherapy). Freedom from additional procedures for clinically significant recurrent disease, including redo-HIFU, was 83%. Post-operative complications included 0.6% new use of pads, 1.3% urethral stricture, 2.6% post-HIFU TURP, and new onset ED of 14%.

Conclusion: In a carefully chosen cohort of patients for focal HIFU our results suggests acceptable oncological control with minimal post-operative morbidity. Further studies are required to establish this technique as a less morbid alternative to radical therapy.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings